| P&L Statement | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue | 5681 | 9524 | 7748 |
| Cost of Material Consumed | 2312 | 3534 | 2213 |
| Change in Inventory | -241 | 160 | 228 |
| Gross Margins | 59.3 | 62.89 | 71.44 |
| Employee Benefit Expenses | 487 | 559 | 599 |
| Other Expenses | 1603 | 2582 | 2426 |
| EBITDA | 1520 | 2689 | 2282 |
| OPM | 26.76 | 28.23 | 29.45 |
| Other Income | 214 | 195 | 55 |
| Finance Cost | 238 | 205 | 233 |
| D&A | 532 | 506 | 473 |
| EBIT | 988 | 2183 | 1809 |
| EBIT Margins | 17.39 | 22.92 | 23.35 |
| PBT | 964 | 2175 | 1616 |
| PBT Margins | 16.97 | 22.84 | 20.86 |
| Tax | 246 | 538 | 387 |
| PAT | 718 | 1637 | 1219 |
| NPM | 12.64 | 17.19 | 15.73 |
| EPS | 14.34 | 32.7 | 24.35 |
| Financial Ratios | 2021 | 2022 | 2023 |
|---|---|---|---|
| Operating Profit Margin | 26.76 | 28.23 | 29.45 |
| Net Profit Margin | 12.64 | 17.19 | 15.73 |
| Earning Per Share (Diluted) | 14.34 | 32.7 | 24.35 |
| Assets | 2021 | 2022 | 2023 |
|---|---|---|---|
| Fixed Assets | 3750 | 3437 | 3131 |
| CWIP | 0 | 0 | 32 |
| Investments | 1026 | 148 | 3850 |
| Trade Receivables | 2346 | 3861 | 3269 |
| Inventory | 583 | 408 | 143 |
| Other Assets | 1938 | 2654 | 1546 |
| Total Assets | 9643 | 10508 | 11971 |
| Liabilities | 2021 | 2022 | 2023 |
|---|---|---|---|
| Share Capital | 500.6 | 500.6 | 500.6 |
| FV | 10 | 10 | 10 |
| Reserves | 5481.2 | 7062 | 8190.5 |
| Borrowings | 2277 | 1869 | 2352 |
| Trade Payables | 590 | 123 | 140 |
| Other Liabilities | 794.2 | 953.4 | 787.9 |
| Total Liabilities | 9643 | 10508 | 11971 |
| Cash-Flow Statement | 2021 | 2022 | 2023 |
|---|---|---|---|
| PBT | 263 | 2513 | 1616 |
| OPBWC | 1302 | 2175 | 2050 |
| Change in Receivables | -1321 | -1515 | 592 |
| Change in Inventories | 0 | 0 | 0 |
| Change in Payables | 732 | -274 | -130 |
| Other Changes | -615 | 414 | 253 |
| Working Capital Change | -1204 | -1375 | 715 |
| Cash Generated From Operations | 98 | 1138 | 2765 |
| Tax | -235 | -595 | -442 |
| Cash Flow From Operations | -137 | 543 | 2323 |
| Purchase of PPE | -74 | -208 | -188 |
| Sale of PPE | 0 | 3 | 3 |
| Cash Flow From Investment | 340 | 1164 | -3598 |
| Borrowing | -688 | -408 | 483 |
| Dividend | -59 | -59 | -74 |
| Equity | 0 | 0 | 0 |
| Others From Financing | 106 | 25 | 10 |
| Cash Flow from Financing | -641 | -442 | 419 |
| Net Cash Generated | -438 | 1265 | -856 |
| Cash at the Start | 509 | 71 | 1336 |
| Cash at the End | 71 | 1336 | 480 |
Premier Cryogenics Limited is a well-established manufacturer of industrial and medical gases, with a strong operational footprint in the production and supply of oxygen, nitrogen, acetylene, and other specialty gases. Founded with the objective of serving essential sectors, the company plays a critical role in catering to industries such as healthcare, metal fabrication, pharmaceuticals, petrochemicals, and engineering. Its manufacturing units are strategically located to ensure efficient distribution across key regions, and the company is known for its consistency, reliable supply chain, and compliance with industrial safety norms. Over the years, Premier Cryogenics has built a reputation for quality, timely delivery, and long-term customer relationships.
From a business standpoint, Premier Cryogenics has benefitted from growing demand for industrial and medical gases, especially following increased healthcare infrastructure development in India. The company’s medical oxygen production capabilities gained prominence during high-demand periods, highlighting its importance in emergency healthcare logistics. Premier Cryogenics also employs advanced manufacturing technologies, stringent quality control, and bulk gas delivery systems that help maintain product purity and operational efficiency. Its focus on safety, plant modernization, and customer service has enabled the company to maintain a stable financial profile and expand its client base across multiple sectors.
In the unlisted shares market, Premier Cryogenics Limited presents an attractive opportunity for investors seeking exposure to a stable, essential-services industry. Demand for industrial and medical gases is expected to remain robust, driven by industrial expansion, healthcare modernization, and increased adoption of specialty gases. While unlisted shares generally come with challenges such as lower liquidity and limited public financial disclosures, Premier Cryogenics’ strong fundamentals, sector relevance, and steady cash flows enhance its investment appeal. For long-term investors looking for a defensive yet growth-oriented sector, Premier Cryogenics Limited stands out as a reliable choice within the unlisted ecosystem.
Q:1 How do I confirm my booking for Premier Cryogenics Limited Unlisted Shares?Answer: You can confirm your booking by contacting us and agreeing on the trading price for the Premier Cryogenics Limited Unlisted Shares.
Q:2 What documents do I need to provide for purchasing the shares?Answer: You need to provide your client master report, PAN Card, and a Cancelled Cheque if you are not transferring funds from the bank account mentioned in the CMR Copy.These documents are required as per SEBI regulations.
Q:3 How do I obtain my client master report?
Answer: You can ask your broker for a copy of your client master report if you do not have it available.
Q:4 What payment methods are accepted for purchasing the shares?Answer: Payments must be made via RTGS, NEFT, IMPS, or cheque transfer.Please note that cash deposits are not accepted.
Q:5 Can I transfer funds from a different bank account than the one mentioned in the CMR?Answer: No, the payment must be made from the same bank account in which the shares are to be credited.
Q:6 Will you provide the bank details for the fund transfer?
Answer: Yes, we will provide you with the bank details once you confirm your booking for the shares.
Q:7 Is there a specific time frame for completing the payment?Answer: While there is no specified time frame mentioned, it is advisable to complete the payment promptly after booking to ensure a smooth transaction.
Q:8 What will happen if I do not provide the required KYC documents?Answer: If the required KYC documents are not provided, the transaction may be delayed or unable to be processed as per SEBI regulations.